Genetics, autoantibodies and clinical features in understanding and
predicting rheumatoid arthritis
Helm-van Mil, A.H.M. van der
Citation
Helm-van Mil, A. H. M. van der. (2006, October 26). Genetics, autoantibodies and clinical
features in understanding and predicting rheumatoid arthritis. Retrieved from
https://hdl.handle.net/1887/4929
Version:
Corrected Publisher’s Version
License:
Licence agreement concerning inclusion of doctoral thesis in the
Institutional Repository of the University of Leiden
Downloaded from:
https://hdl.handle.net/1887/4929
#HA P TER¬ !"342!#4 /BJECTIVES 4O¬INVESTIGATE¬THE¬PREDICTIVE¬VALUE¬OF¬THE¬DISTRIBUTION¬OF¬INm¬AMED¬JOINTS¬AT¬ l¬RST¬PRESENTATION¬FOR¬THE¬SEVERITY¬OF¬THE¬DISEASE¬COURSE¬IN¬2! -ETHODS &ROM¬¬CONSECUTIVE¬PATIENTS¬INCLUDED¬IN¬THE¬,EIDEN¬%ARLY¬!RTHRITIS¬#LINIC ¬
¬ PATIENTS¬ FULl¬LLED¬ THE¬ !#2 CRITERIA¬ FOR¬ 2!¬ WITHIN¬ YEAR¬ OF¬ FOLLOW UP¬ /F¬ THESE ¬ PATIENTS¬ ACHIEVED¬ REMISSION¬ 2ADIOGRAPHS¬ OF¬ HANDS¬ AND¬ FEET¬ WERE¬ SCORED¬ ACCORDING¬ TO¬ THE¬3HARP VAN¬DER¬(EIJDE¬METHOD¬AND¬THE¬¬PATIENTS¬WITH¬THE¬MOST¬DESTRUCTIVE¬DISEASE WERE¬SELECTED¬4HE¬DISTRIBUTION¬OF¬INm¬AMED¬JOINTS¬OF¬THE¬PATIENTS¬WITH¬THE¬EXTREME¬DISEASE COURSES¬WAS¬COMPARED¬4HE¬ASSOCIATION¬BETWEEN¬THE¬DISTRIBUTION¬OF¬INm¬AMED¬JOINTS¬AND¬ THE¬LEVEL¬OF¬DESTRUCTION¬OF¬THE¬JOINTS¬OF¬HANDS¬AND¬FEET¬IN¬THE¬WHOLE¬GROUP¬OF¬2! PATIENTS WAS¬ASSESSED¬USING¬REGRESSION¬ANALYSIS 2ESULTS #OMPARISON¬OF¬THE¬PATIENTS¬WITH¬EXTREME¬DISEASE¬COURSES¬USING¬UNIVARIATE¬AND¬
LOGISTIC¬ REGRESSION¬ ANALYSES¬ REVEALED¬ THAT¬ ARTHRITIS¬ OF¬ THE¬ LARGE¬ JOINTS ¬ IN¬ PARTICULAR¬ THE¬ KNEE ¬WAS¬ASSOCIATED¬WITH¬SEVERE¬2!¬)N¬THE¬WHOLE¬GROUP¬OF¬2! PATIENTS ¬THE¬TOTAL¬NUMBER OF¬ SWOLLEN¬ JOINTS¬ AND¬ THE¬ PRESENCE¬ OF¬ KNEE¬ ARTHRITIS¬ ASSOCIATED¬ INDEPENDENTLY¬ WITH¬ THE LEVEL¬OF¬DESTRUCTION¬OF¬THE¬SMALL¬JOINTS¬2! PATIENTS¬WITH¬KNEE¬ARTHRITIS¬HAD¬HIGHER¬# REAC TIVE¬PROTEIN¬LEVELS¬THAN¬PATIENTS¬WITHOUT¬KNEE¬ARTHRITIS¬AND¬INVESTIGATING¬THE¬DISTRIBUTION OF¬ INm¬AMED¬ JOINTS¬ TOGETHER¬ WITH¬ OTHER¬ VARIABLES¬ YIELDED¬ THE¬ NUMBER¬ OF¬ SWOLLEN¬ JOINTS # REACTIVE¬PROTEIN¬LEVEL ¬PRESENCE¬OF¬ANTI ##0¬ANTIBODIES¬AND¬SYMPTOM¬DURATION¬AS¬PRE DICTORS¬FOR¬2!¬SEVERITY
#ONCLUSIONS !RTHRITIS¬OF¬LARGE¬JOINTS ¬IN¬PARTICULAR¬THE¬KNEE ¬AT¬l¬RST¬PRESENTATION¬IS¬AS
#HA P TER¬ ARTHRITIS¬FOR¬FURTHER¬READING¬SEE¬ ¬)N¬THE¬STUDY¬PERIOD¬ ¬¬PATIENTS¬WITH EARLY¬ARTHRITIS¬WERE¬INCLUDED¬!FTER¬ONE¬YEAR¬FOLLOW UP ¬¬PATIENTS¬HAD¬FULl¬LLED¬THE¬ !#2 CRITERIA¬FOR¬2!¬ ¬&ROM¬THESE¬2!¬PATIENTS ¬TWO¬CATEGORIES¬OF¬PATIENTS¬WITH¬EXTREME¬ DISEASE¬COURSES¬WERE¬SELECTED¬THOSE¬WHO¬ENTERED¬SUSTAINED¬REMISSION¬REMITTING¬2! ¬AND THOSE¬HAD¬PROGRESSED¬TO¬THE¬MOST¬DESTRUCTIVE¬DISEASE¬SEVERE¬2! ¬2EMISSION¬WAS¬DEl¬NED AS¬SATISFYING¬THE¬PROPOSED¬!MERICAN¬2HEUMATISM¬!SSOCIATION¬!2! ¬CRITERIA¬FOR¬CLINICAL¬ REMISSION¬ ¬ AFTER¬ HAVING¬ DISCONTINUED¬ THE¬ USE¬ OF¬ $ISEASE¬ -ODIFYING¬ !NTIRHEUMATIC $RUGS¬$-!2$S ¬FOR¬AT¬LEAST¬ONE¬YEAR¬!FTER¬ONE¬ADDITIONAL¬YEAR¬OF¬FOLLOW UP¬THE¬PRESENCE OF¬SUSTAINED¬REMISSION¬WAS¬CONl¬RMED¬¬PATIENTS¬HAD¬ACHIEVED¬SUSTAINED¬REMISSION¬AFTER MEAN¬DISEASE¬DURATION¬OF¬¬YEARS¬RANGE¬ ¬DAYS¬3$¬¬DAYS ¬&OR¬MORE¬DETAILS¬ ON¬ THESE¬ PATIENTS¬ SEE¬ ¬ 4HE¬ REMITTING¬ PATIENTS¬ ARE¬ FURTHER¬ REFERRED¬ TO¬ AS¬ hREMITTING¬ 2!v¬2ADIOGRAPHS¬OF¬THE¬HANDS¬AND¬FEET¬WERE¬TAKEN¬AT¬BASELINE¬AND¬YEARLY¬THEREAFTER¬AND THE¬LEVEL¬OF¬RADIOLOGICAL¬JOINT¬DESTRUCTION¬WAS¬SCORED¬ACCORDING¬TO¬THE¬3HARP VAN¬DER¬(EI JDE¬METHOD¬ ¬4HE¬RHEUMATOLOGIST¬THAT¬SCORED¬THE¬RADIOGRAPHS¬WAS¬UNAWARE¬OF¬THE¬ STUDY¬QUESTION¬4HE¬PATIENTS¬WITH¬THE¬MOST¬DESTRUCTIVE¬DISEASE¬COURSE¬WERE¬IDENTIl¬ED¬BY SELECTING¬THE¬¬PATIENTS¬THAT¬HAD¬THE¬HIGHEST¬3HARP VAN¬DER¬(EIJDE¬SCORES¬AFTER¬ONE¬YEAR¬ OF¬FOLLOW UP¬4HIS¬CORRESPONDED¬WITH¬A¬3HARP VAN¬DER¬(EIJDE¬SCORE¬ ¬MEAN¬ 4HESE PATIENTS¬ARE¬FURTHER¬REFERRED¬TO¬AS¬hMOST¬SEVERE¬2!v -ETHODS
#HA P TER¬ 3TUDIES¬THAT¬INVESTIGATE¬THE¬NATURAL¬DISEASE¬COURSE¬IN¬2!¬ARE¬NOWADAYS¬HAMPERED¬BY¬THE¬ FACT¬THAT¬AGGRESSIVE¬AND¬EFFECTIVE¬DISEASE¬MODIFYING¬ANTIRHEUMATIC¬DRUGS¬INCLUDING¬BIO LOGICALS¬ARE¬USED¬4HE¬EFFECTIVE¬REDUCTION¬OF¬THE¬DISEASE¬ACTIVITY¬DIMINISHES¬THE¬LEVEL¬OF¬ JOINT¬DESTRUCTION¬$ESPITE¬THE¬INDISPUTABLE¬BENEl¬T¬FOR¬2!¬PATIENTS ¬THE¬NATURAL¬COURSE¬OF¬ THE¬DISEASE¬IS¬ALTERED¬AND¬THE¬PATIENTS¬THAT¬ARE¬CURRENTLY¬TREATED¬FOR¬2!¬ARE¬LESS¬SUITABLE¬ FOR¬STUDIES¬THAT¬AIM¬TO¬IDENTIFY¬VARIABLES¬THAT¬PREDICT¬THE¬DISEASE¬OUTCOME¬4HE¬PATIENTS INCLUDED¬IN¬THE¬PRESENT¬STUDY¬WERE¬TREATED¬FOR¬2!¬BETWEEN¬¬AND¬¬)N¬THIS¬TIME ERA ¬THERAPY¬WITH¬$-!2$S¬WAS¬STARTED¬IN¬A¬RELATIVELY¬LATE¬STAGE¬AND¬MEDICATIONS¬OF¬CHOICE¬ WERE¬ AMONG¬ OTHERS¬ ANTIMALARIALS ¬ OF¬ WHICH¬ IS¬ KNOWN¬ THAT¬ THEIR¬ ABILITY¬ TO¬ HALT¬ DISEASE¬ PROGRESSION¬IS¬LIMITED¬.ONE¬OF¬THE¬INCLUDED¬PATIENTS¬WERE¬TREATED¬WITH¬BIOLOGICALS¬&ROM¬ THE¬¬PATIENTS¬THAT¬ACHIEVED¬SUSTAINED¬REMISSION¬¬PATIENTS¬HAD¬RECEIVED¬NO¬$-!2$ THERAPY ¬¬WERE¬TREATED¬WITH¬ANTIMALARIALS¬AND¬THE¬REMAINING¬¬WERE¬PRESCRIBED¬METHO TREXATE¬OR¬SULPHASALAZINE¬4HE¬PATIENTS¬INCLUDED¬IN¬THE¬PRESENT¬STUDY¬ARE¬MORE¬SUITABLE¬FOR¬ A¬STUDY¬ASSESSING¬RISK¬FACTORS¬FOR¬2!¬SEVERITY ¬THAN¬THE¬PATIENTS¬THAT¬ARE¬NOWADAYS¬INCLUDED IN¬OUR¬%ARLY¬!RTHRITIS¬#LINIC
!RTHRITIS¬OF¬LARGE¬JOINTS ¬PARTICULARLY¬THE¬KNEE ¬PREDICTS¬SEVERE¬2!
2%&%2%.#%3¬
¬ ¬ 1UINN¬ -! ¬ %MERY¬ 0¬ 0OTENTIAL¬ FOR¬ ALTERING¬ RHEUMATOID¬ ARTHRITIS¬ OUTCOME¬ 2HEUM¬ $IS¬ .ORTH¬!M¬ ¬ ¬ 1UINN¬-! ¬#OX¬3¬4HE¬EVIDENCE¬FOR¬EARLY¬INTERVENTION¬2HEUM¬$IS¬.ORTH¬!M¬¬ ¬ ¬ %MERY¬0¬4REATMENT¬OF¬RHEUMATOID¬ARTHRITIS¬"-*¬ ¬ ¬ 6ISSER¬( ¬LE¬#ESSIE¬3 ¬6OS¬+ ¬"REEDVELD¬&# ¬(AZES¬*-¬(OW¬TO¬DIAGNOSE¬2HEUMATOID¬!R THRITIS¬EARLY¬A¬PREDICTION¬MODEL¬FOR¬PERSISTENT¬EROSIVE ¬ARTHRITIS¬!RTHRITIS¬2HEUM¬¬ ¬ ¬ 6ISSER¬(¬%ARLY¬DIAGNOSIS¬OF¬2HEUMATOID¬!RTHRITIS¬"EST¬0RACT¬2ES¬#LIN¬2HEUMATOL¬¬ ¬
¬ ¬ "RENNAN¬ 0 ¬ (ARRISSON¬ "¬ !¬ SIMPLE¬ ALGORITHM¬ TO¬ PREDICT¬ THE¬ DEVELOPMENT¬ OF¬ RADIOLOGI CAL¬EROSIONS¬IN¬PATIENTS¬WITH¬EARLY¬RHEUMATOID¬ARTHRITIS¬PROSPECTIVE¬COHORT¬STUDY¬"-*¬
¬ ¬ 'ORMAN¬ *$ ¬ ,UM¬ 2& ¬ #HEN¬ ** ¬ 3UAREZ !LMAZOR¬ -% ¬ 4HOMSON¬ ' ¬ #RISWELL¬ ,!¬ )MPACT¬ OF¬SHARED¬EPITOPE¬GENOTYPE¬AND¬ETHNICITY¬ON¬EROSIVE¬DISEASE¬A¬META ANALYSIS¬OF¬ RHEUMATOID¬ARTHRITIS¬PATIENTS¬!RTHRITIS¬2HEUM¬¬ ¬
¬ ¬ 6AN¬DER¬(ELM VAN¬-IL¬!( ¬6ERPOORT¬+. ¬"REEDVELD¬&# ¬4OES¬2% ¬(UIZINGA ¬47*¬!NTI BODIES¬ TO¬ CITRULLINATED¬ PROTEINS¬ AND¬ DIFFERENCES¬ IN¬ CLINICAL¬ PROGRESSION¬ OF¬ RHEUMATOID¬ ARTHRITIS¬!RTHRITIS¬2ES¬4HER¬¬¬ 2¬
¬ ¬ VAN¬'AALEN¬&! ¬,INN 2ASKER¬30 ¬6AN¬6ENROOIJ¬7* ¬DE¬*ONG¬"! ¬"REEDVELD¬&# ¬6ERWEIJ¬#, 4OES¬2% ¬(UIZINGA¬47¬!UTOANTIBODIES¬TO¬CYCLIC¬CITRULLINATED¬PEPTIDES¬PREDICT¬PROGRES SION¬ TO¬ RHEUMATOID¬ ARTHRITIS¬ IN¬ PATIENTS¬ WITH¬ UNDIFFERENTIATED¬ ARTHRITIS¬ A¬ PROSPECTIVE COHORT¬STUDY¬!RTHRITIS¬2HEUM¬¬ ¬ ¬ 2AZA¬+ ¬"REESE¬- ¬.IGHTINGALE¬0 ¬+UMAR¬+ ¬0OTTER¬4 ¬#ARRUTHERS¬$- ¬3ITUNAYAKE¬$ ¬'OR DON¬# ¬"UCKLEY¬#$ ¬3ALMON¬- ¬+ITAS¬'$¬0REDICTIVE¬VALUE¬OF¬ANTIBODIES¬TO¬CYCLIC¬CITRUL LINATED¬PEPTIDE¬IN¬PATIENTS¬WITH¬VERY¬EARLY¬INm¬AMMATORY¬ARTHRITIS¬*¬2HEUMATOL¬ ¬ ¬ ¬ ¬ +AARELA¬+ ¬,UUKKAINEN¬2 ¬+OSKIMIES¬3¬(OW¬OFTEN¬IS¬SEROPOSITIVE¬RHEUMATOID¬ARTHRITIS¬AN EROSIVE¬DISEASE ¬!¬¬YEAR¬FOLLOW UP¬STUDY¬*¬2HEUMATOL¬¬¬ ¬ ¬ ¬ "AS¬3 ¬'ENEVAY¬3 ¬-EYER¬/ ¬'ABAY¬#¬!NTI CYCLIC¬CITRULLINATED¬PEPTIDE¬ANTIBODIES ¬)G-AND¬ )G!¬ RHEUMATOID¬ FACTORS¬ IN¬ THE¬ DIAGNOSIS¬ "AS¬3 ¬'ENEVAY¬3 ¬-EYER¬/ ¬'ABAY¬#¬!NTI CYCLIC¬CITRULLINATED¬PEPTIDE¬ANTIBODIES ¬)G-AND¬ PROGNOSIS¬ OF¬ RHEUMATOID¬ ARTHRITIS 2HEUMATOLOGY¬/XFORD ¬¬
¬ ¬ 3TOCKMAN¬ ! ¬ 4AIT¬ "$ ¬ 7OLFE¬ 2 ¬ "RAND¬ #! ¬ 2OWLEY¬ -* ¬ 6ANNEY¬ -$ ¬ "UCHBINDER¬ 2- ¬ -UIRDEN¬+$¬#LINICAL¬LABORATORY¬AND¬GENETIC¬MARKERS¬ASSOCIATED¬WITH¬EROSIONS¬AND¬RE MISSION¬IN¬PATIENTS¬WITH¬EARLY¬INm¬AMMATORY¬ARTHRITIS¬A¬PROSPECTIVE¬COHORT¬STUDY¬2HEU MATOLOGY¬)NT¬¬
¬ ¬ $IXEY¬ * ¬ 3OLYMOSSY¬ # ¬ 9OUNG¬ ! ¬ %ARLY¬ 2!¬ 3TUDY¬ )S¬ IT¬ POSSIBLE¬ TO¬ PREDICT¬ RADIOLOGICAL¬ DAMAGE¬IN¬EARLY¬RHEUMATOID¬ARTHRITIS ¬!¬REPORT¬ON¬THE¬OCCURRENCE ¬PROGRESSION¬AND¬PROG NOSTIC¬FACTORS¬OF¬RADIOLOGICAL¬EROSIONS¬OVER¬THE¬l¬RST¬¬YEARS¬IN¬¬PATIENTS¬FROM¬THE¬%ARLY¬ 2!¬STUDY¬%2!3 ¬*¬2HEUMATOL¬3UPPL¬¬¬
#HA P TER¬ AGAINST¬CYCLIC¬CITRULLINATED¬PEPTIDE¬BEFORE¬AND¬AT¬DISEASE¬ONSET ¬AND¬BY¬)G! RHEUMATOID FACTOR¬AT¬DISEASE¬ONSET¬!NN¬2HEUM¬$IS¬¬!PRIL
¬ ¬ VAN¬ !KEN¬ * ¬ VAN¬ "ILSEN¬ *( ¬ !LLAART¬ #& ¬ (UIZINGA¬ 47 ¬ "REEDVELD¬ &#¬ 4HE¬ ,EIDEN¬ %ARLY !RTHRITIS¬#LINIC¬#LIN¬%XP¬2HEUMATOL¬¬¬3UPPL¬ 3 3 ¬ ¬ !RNETT¬&# ¬%DWORTHY¬3- ¬"LOCH¬$! ¬-C3HANE¬$* ¬&RIES¬*& ¬#OOPER¬.3 ¬(EALY¬,! ¬+APLAN 32 ¬,IANG¬-( ¬,UTHRA¬(3¬4HE¬!MERICAN¬2HEUMATISM¬!SSOCIATION¬¬REVISED¬CRITERIA¬ FOR¬THE¬CLASSIl¬CATION¬OF¬RHEUMATOID¬ARTHRITIS¬!RTHRITIS¬2HEUM¬¬ ¬ ¬ 0INALS¬2! ¬-ASAI¬!4 ¬,ARSEN¬2!¬0RELIMINARY¬CRITERIA¬FOR¬CLINICAL¬REMISSION¬IN¬RHEUMATOID ARTHRITIS¬!RTHRITIS¬2HEUM¬¬¬ ¬ ¬ ,INN 2ASKER¬30 ¬!LLAART¬#& ¬+LOPPENBURG¬- ¬"REEDVELD¬&# ¬(UIZINGA¬47*¬3USTAINED¬RE MISSION¬IN¬A¬COHORT¬OF¬PATIENTS¬WITH¬RHEUMATOID¬ARTHRITIS¬ASSOCIATION¬WITH¬ABSENCE¬OF¬ )G-¬ 2&¬ AND¬ ABSENCE¬ OF¬ ANTI ##0¬ ANTIBODIES¬ )NT¬ *¬ !DVANCES¬ 2HEUMATOLOGY¬ ¬
¬ ¬ 6AN¬DER¬(EIDE¬$-¬0LAIN¬8 RAYS¬IN¬RHEUMATOID¬ARTHRITIS¬OVERVIEW¬OF¬SCORING¬METHODS ¬ THEIR¬RELIABILITY¬AND¬APPLICABILITY¬"AILLIERES¬#LIN¬2HEUMATOL¬
¬ ¬ 6AN¬DER¬(EIDE¬$¬(OW¬TO¬READ¬RADIOGRAPHS¬ACCORDING¬TO¬THE¬3HARP VAN¬DER¬(EIJDE¬METH OD¬*¬2HEUMATOL¬
¬ ¬ 6ISSER¬ ( ¬ 'ELINCK¬ ," ¬ +AMPFRAATH¬ !( ¬ "REEDVELD¬ &# ¬ (AZES¬ *-¬ $IAGNOSTIC¬ AND¬ PROG NOSTIC¬ CHARACTERISTICS¬ OF¬ ENZYME¬ LINKED¬ IMMUNOSORBENT¬ RHEUMATOID¬ FACTOR¬ ASSAYS¬ IN RHEUMATOID¬ARTHRITIS¬!NN¬2HEUM¬$IS¬
